MBX Stock Overview
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Microbix Biosystems Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.34 |
| 52 Week High | CA$0.47 |
| 52 Week Low | CA$0.23 |
| Beta | 0.23 |
| 1 Month Change | -12.99% |
| 3 Month Change | -16.25% |
| 1 Year Change | -11.84% |
| 3 Year Change | -45.08% |
| 5 Year Change | 19.64% |
| Change since IPO | -44.17% |
Recent News & Updates
Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem
Feb 21
Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 17Recent updates
Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem
Feb 21Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 17Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up
Dec 23Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?
Nov 03Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?
Jul 22Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio
May 17Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook
Dec 27Microbix Biosystems (TSE:MBX) Has A Pretty Healthy Balance Sheet
Aug 08Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals
May 20Microbix Biosystems (TSE:MBX) Seems To Use Debt Quite Sensibly
Feb 06One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates
Dec 28Is Microbix Biosystems (TSE:MBX) A Risky Investment?
Oct 14Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 15A Look At The Fair Value Of Microbix Biosystems Inc. (TSE:MBX)
May 17Most Shareholders Will Probably Find That The CEO Compensation For Microbix Biosystems Inc. (TSE:MBX) Is Reasonable
Mar 24We Think Microbix Biosystems (TSE:MBX) Has A Fair Chunk Of Debt
Jan 29
Shareholder Returns
| MBX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -5.6% | -1.1% | 0.7% |
| 1Y | -11.8% | -38.2% | 5.5% |
Return vs Industry: MBX exceeded the Canadian Biotechs industry which returned -38.2% over the past year.
Return vs Market: MBX underperformed the Canadian Market which returned 5.5% over the past year.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MBX's share price has been volatile over the past 3 months.
Volatility Over Time: MBX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Cameron Groome | www.microbix.com |
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Microbix Biosystems Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | CA$46.03m |
| Earnings (TTM) | CA$3.72m |
| Revenue (TTM) | CA$22.42m |
12.4x
P/E Ratio2.1x
P/S RatioIs MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | CA$22.42m |
| Cost of Revenue | CA$9.90m |
| Gross Profit | CA$12.52m |
| Other Expenses | CA$8.80m |
| Earnings | CA$3.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.027 |
| Gross Margin | 55.83% |
| Net Profit Margin | 16.57% |
| Debt/Equity Ratio | 21.5% |
How did MBX perform over the long term?
See historical performance and comparison